These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 34824158)

  • 1. Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy.
    Alvarez M; Molina C; De Andrea CE; Fernandez-Sendin M; Villalba M; Gonzalez-Gomariz J; Ochoa MC; Teijeira A; Glez-Vaz J; Aranda F; Sanmamed MF; Rodriguez-Ruiz ME; Fan X; Shen WH; Berraondo P; Quintero M; Melero I
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34824158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral BO-112 in combination with radiotherapy synergizes to achieve CD8 T-cell-mediated local tumor control.
    Rodriguez-Ruiz ME; Serrano-Mendioroz I; Garate-Soraluze E; Sánchez-Mateos P; Barrio-Alonso C; Rodríguez López I; Diaz Pascual V; Arbea Moreno L; Alvarez M; Sanmamed MF; Perez-Gracia JL; Escuin-Ordinas H; Quintero M; Melero I
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36631161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapeutic effects of intratumoral nanoplexed poly I:C.
    Aznar MA; Planelles L; Perez-Olivares M; Molina C; Garasa S; Etxeberría I; Perez G; Rodriguez I; Bolaños E; Lopez-Casas P; Rodriguez-Ruiz ME; Perez-Gracia JL; Marquez-Rodas I; Teijeira A; Quintero M; Melero I
    J Immunother Cancer; 2019 May; 7(1):116. PubMed ID: 31046839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of LCMV-based cancer immunotherapies is unleashed by intratumoral injections of polyI:C.
    Gomar C; Di Trani CA; Bella A; Arrizabalaga L; Gonzalez-Gomariz J; Fernandez-Sendin M; Alvarez M; Russo-Cabrera JS; Ardaiz N; Aranda F; Schippers T; Quintero M; Melero I; Orlinger KK; Lauterbach H; Berraondo P
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38631714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intratumoral injection of interferon-α and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy.
    Dubrot J; Palazón A; Alfaro C; Azpilikueta A; Ochoa MC; Rouzaut A; Martinez-Forero I; Teijeira A; Berraondo P; Le Bon A; Hervás-Stubbs S; Melero I
    Int J Cancer; 2011 Jan; 128(1):105-18. PubMed ID: 20309938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumoral Immunotherapy with XCL1 and sFlt3L Encoded in Recombinant Semliki Forest Virus-Derived Vectors Fosters Dendritic Cell-Mediated T-cell Cross-Priming.
    Sánchez-Paulete AR; Teijeira Á; Quetglas JI; Rodríguez-Ruiz ME; Sánchez-Arráez Á; Labiano S; Etxeberria I; Azpilikueta A; Bolaños E; Ballesteros-Briones MC; Casares N; Quezada SA; Berraondo P; Sancho D; Smerdou C; Melero I
    Cancer Res; 2018 Dec; 78(23):6643-6654. PubMed ID: 30297531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic.
    Alvarez M; Molina C; Garasa S; Ochoa MC; Rodriguez-Ruiz ME; Gomis G; Cirella A; Olivera I; Glez-Vaz J; Gonzalez-Gomariz J; Luri-Rey C; Azpilikueta A; Bolaños E; Teijeira A; Berraondo P; Quintero M; Melero I
    Oncoimmunology; 2023; 12(1):2197370. PubMed ID: 37035637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intratumoral injection of interferon-gamma gene-modified dendritic cells elicits potent antitumor effects: effective induction of tumor-specific CD8+ CTL response.
    Pan J; Zhang M; Wang J; Wang Q; Xia D; Sun W; Zhang L; Yu H; Cao X
    J Cancer Res Clin Oncol; 2005 Jul; 131(7):468-78. PubMed ID: 15711825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity.
    Demaria O; De Gassart A; Coso S; Gestermann N; Di Domizio J; Flatz L; Gaide O; Michielin O; Hwu P; Petrova TV; Martinon F; Modlin RL; Speiser DE; Gilliet M
    Proc Natl Acad Sci U S A; 2015 Dec; 112(50):15408-13. PubMed ID: 26607445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STING Activated Tumor-Intrinsic Type I Interferon Signaling Promotes CXCR3 Dependent Antitumor Immunity in Pancreatic Cancer.
    Vonderhaar EP; Barnekow NS; McAllister D; McOlash L; Eid MA; Riese MJ; Tarakanova VL; Johnson BD; Dwinell MB
    Cell Mol Gastroenterol Hepatol; 2021; 12(1):41-58. PubMed ID: 33548597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancing immunotherapy of STING agonist for lymphoma in preclinical models.
    Sallets A; Robinson S; Kardosh A; Levy R
    Blood Adv; 2018 Sep; 2(17):2230-2241. PubMed ID: 30194137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
    Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
    Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of injection technique, drug formulation and tumor microenvironment on intratumoral immunotherapy delivery and efficacy.
    Muñoz NM; Williams M; Dixon K; Dupuis C; McWatters A; Avritscher R; Manrique SZ; McHugh K; Murthy R; Tam A; Naing A; Patel SP; Leach D; Hartgerink JD; Young S; Prakash P; Hwu P; Sheth RA
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epitope spreading driven by the joint action of CART cells and pharmacological STING stimulation counteracts tumor escape via antigen-loss variants.
    Conde E; Vercher E; Soria-Castellano M; Suarez-Olmos J; Mancheño U; Elizalde E; Rodriguez ML; Glez-Vaz J; Casares N; Rodríguez-García E; Hommel M; González-Aseguinolaza G; Uranga-Murillo I; Pardo J; Alkorta G; Melero I; Lasarte J; Hervas-Stubbs S
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34810235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
    Wang D; Jiang W; Zhu F; Mao X; Agrawal S
    Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
    Jassar AS; Suzuki E; Kapoor V; Sun J; Silverberg MB; Cheung L; Burdick MD; Strieter RM; Ching LM; Kaiser LR; Albelda SM
    Cancer Res; 2005 Dec; 65(24):11752-61. PubMed ID: 16357188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells.
    Wang S; Campos J; Gallotta M; Gong M; Crain C; Naik E; Coffman RL; Guiducci C
    Proc Natl Acad Sci U S A; 2016 Nov; 113(46):E7240-E7249. PubMed ID: 27799536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poly-IC enhances the effectiveness of cancer immunotherapy by promoting T cell tumor infiltration.
    Sultan H; Wu J; Fesenkova VI; Fan AE; Addis D; Salazar AM; Celis E
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32958686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors.
    Márquez-Rodas I; Longo F; Rodriguez-Ruiz ME; Calles A; Ponce S; Jove M; Rubio-Viqueira B; Perez-Gracia JL; Gómez-Rueda A; López-Tarruella S; Ponz-Sarvise M; Álvarez R; Soria-Rivas A; de Miguel E; Ramos-Medina R; Castañon E; Gajate P; Sempere-Ortega C; Jiménez-Aguilar E; Aznar MA; Calvo A; Lopez-Casas PP; Martín-Algarra S; Martín M; Tersago D; Quintero M; Melero I
    Sci Transl Med; 2020 Oct; 12(565):. PubMed ID: 33055241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regression of established AB1 murine mesothelioma induced by peritumoral injections of CpG oligodeoxynucleotide either alone or in combination with poly(I:C) and CD40 ligand plasmid DNA.
    Stone GW; Barzee S; Snarsky V; Santucci C; Tran B; Kornbluth RS
    J Thorac Oncol; 2009 Jul; 4(7):802-8. PubMed ID: 19550243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.